Test Price
800 AEDโ Home Collection Available
Malaria P. falciparum & P. vivax Multiplex RNA Detection Qualitative Test in Dubai, UAE
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Real-Time RT-PCR Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance for Result Interpretation by DHA-Licensed Physicians.
Insurance: Direct Billing Verification & Fast-Track Approval via WhatsApp +971 54 548 8731.
This molecular assay delivers definitive detection and species differentiation of Plasmodium falciparum and Plasmodium vivax RNA using real-time reverse transcription polymerase chain reaction, fully compliant with DHA diagnostic standards and UAE federal health regulations.
Test Overview & Methodology
Our state-of-the-art real-time RT-PCR test definitively detects and differentiates Plasmodium falciparum and Plasmodium vivax RNA in whole blood or dried blood spots, delivering actionable results within 36 to 48 hours. This molecular approach outperforms conventional blood smear microscopy in sensitivity and species identification, enabling targeted antimalarial therapy.
| Feature | Our Test (RNA Multiplex RT-PCR) | Traditional Blood Smear Microscopy |
|---|---|---|
| Methodology | Real-Time RT-PCR (qPCR), Whole Genome Sequencing validation | Giemsa-stained thick and thin films |
| Analytical Sensitivity | โฅ99.9% (detects <1 parasite/ยตL) | 50โ80% in field settings, highly operator-dependent |
| Species Differentiation | Automated multiplex detection of P. falciparum & P. vivax | Requires expert microscopy; frequent misidentification |
| Turnaround Time | 36โ48 hours (phone or email) | 2โ4 hours, but repeat smears often necessary |
| Guideline Compliance | DHA and MOHAP Standards, ISO 9001:2015 | WHO reference method, quality varies |
Physician Insight & Safety Protocols
Accurate species identification in malaria directly influences therapeutic decisions: P. falciparum carries a higher risk of severe disease and requires prompt artemisinin-based combination therapy, while P. vivax necessitates additional radical cure with primaquine to eradicate hypnozoites and prevent relapse. This RNA-based multiplex assay provides the molecular clarity needed to tailor treatment and monitor parasitemia with confidence. Always integrate laboratory findings with clinical assessment and travel epidemiology.
โ Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
โ ๏ธ Medication & Safety Advisory
Do not discontinue any prescribed antimalarial, antibiotic, or chronic medication without direct consultation with your treating physician. This test is a diagnostic tool, not a substitute for clinical judgment. Continue all medications as directed until your doctor advises otherwise.
Exclusion Criteria & Emergency Red Flags
Do Not Proceed with Home Collection if:
- Patient is hemodynamically unstable (systolic BP <90 mmHg, altered consciousness).
- Severe anemia (Hb <7 g/dL) requiring immediate transfusion.
- Active seizures or signs of cerebral malaria.
- Inability to provide informed consent or legal guardian not present for minors.
Seek Emergency Care Immediately if:
- Confusion, drowsiness, or coma.
- Jaundice, dark urine, or easy bruising.
- Respiratory distress or oxygen saturation <92%.
- Parasitemia >5% on any previous smear.
- Severe vomiting precluding oral intake.
These safety checks align with the UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and standard clinical protocols.
Patient FAQ & Clinical Guidance
1. What exactly does the Malaria Multiplex RNA Detection test measure?
This molecular assay directly identifies and distinguishes Plasmodium falciparum and Plasmodium vivax RNA in whole blood with high precision. It employs real-time reverse transcription PCR to amplify species-specific genetic sequences, confirming active infection even before symptoms peak. The qualitative result (detected or not detected) allows clinicians to initiate the correct antimalarial regimen, addressing treatment gaps for P. vivax hypnozoites and preventing relapse.
2. How should I prepare for the blood draw?
No fasting is required. Simply sign the clinical consent form and bring your complete medical and travel history. You will need to provide a valid Emirates ID or passport, and our mobile phlebotomist will verify your details. If you are taking any antimalarial drugs or antibiotics, continue them unless instructed otherwise by your doctor. The sample is collected in a standard EDTA tube for whole blood or on a dried blood spot card for infants and remote collection scenarios.
3. When will I receive my results and how are they reported?
Preliminary results are shared by phone within 36 hours, and an official email PDF report follows within 48 hours. The final report includes qualitative outcomes for each species (Detected or Not Detected), assay validation data, LOINC codes, and interpretation notes by DHA-licensed consultants. Results are encrypted and transmitted in full compliance with UAE data protection law, and you may schedule a free tele-guidance call to discuss the findings with our medical team.
4. What is the difference between this RNA test and a standard blood smear?
A standard blood smear relies on visual identification of parasites under a microscope and requires significant expertise, often missing low-density infections or misidentifying species. Our RNA-based RT-PCR test amplifies parasite genetic material, achieving sensitivity below one parasite per microliter and delivering automated species differentiation. This molecular method provides a definitive diagnosis even in patients with early or subclinical malaria, ensuring timely and appropriate treatment.
5. Are there any restrictions after the sample is collected?
No specific restrictions apply after blood collection. You may resume normal activities immediately. Our phlebotomist will apply a small bandage over the venipuncture site, which can be removed after a few hours. If you experience unusual bleeding, swelling, or discomfort at the puncture site, please contact our support team or your physician.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates under DHA Facility License Number 1143 and adheres to the highest standards of data protection and clinical safety. All patient information is processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing, patient consent, and safety protocols follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. Your health data is encrypted, access-controlled, and never shared without your explicit consent.
Clinical & Logistical Metadata
| Test Name | Malaria P. falciparum & P. vivax Multiplex RNA Detection (Qualitative) |
| Price (AED) | 800 AED |
| Turnaround Time | 36โ48 Hours |
| Sample Type / Matrix | Whole Blood (EDTA) or Dried Blood Spots |
| Methodology Used | Real-Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR) |
| ICD-10-CM Code | B50.9, B51.9 |
| LOINC Code | 49576-6 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians